---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-116642"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:05:55.428577+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809

## Summary
- Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.
- Cash and equivalents of $930M at Sept 30, 2024, up from $362M at Dec 31, 2023.
- End-of-Phase 2 meeting for subcutaneous VK2735 (obesity) planned for 4Q24; Phase 2 oral VK2735 trial expected to start 4Q24.
- Positive Phase 2b VOYAGE results for VK2809 in NASH/MASH with fibrosis selected for oral presentation at AASLD Nov 19.
- Positive Phase 1b results for VK0214 in X-ALD show reductions in very long-chain fatty acids and plasma lipids.

## SEC filing metadata
- accession: 0000950170-24-116642
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024116642/0000950170-24-116642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024116642/vktx-20241023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-116642
- JSON: https://secwatch.observer/filing/0000950170-24-116642.json
- Plain text: https://secwatch.observer/filing/0000950170-24-116642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.